TY - JOUR A1 - Steinseifer, Ulrich A1 - Kashefi, Ali A1 - Hormes, Marcus A1 - Schoberer, Mark A1 - Orlikowsky, Thorsten A1 - Behbahani, Mehdi A1 - Behr, Marek A1 - Schmitz-Rode, Thomas T1 - Miniaturization of ECMO Systems : Engineering Challenges and Methods JF - Artificial Organs. 33 (2009), H. 5 Y1 - 2009 SN - 1525-1594 N1 - Fifth International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion Abstracts SP - A55 EP - A55 ER - TY - JOUR A1 - Jansen, Sebastian A1 - Behbahani, Mehdi A1 - Laumen, Marco A1 - Kaufmann, Tim A1 - Hormes, Marcus A1 - Schmitz-Rode, Thomas A1 - Behr, Marek A1 - Steinseifer, Ulrich T1 - 3D Stereo-PIV Validation for CFD-Simulation of Steady Flow through the Human Aorta using Rapid-Prototyping techniques Y1 - 2010 N1 - abstract ; IV International Symposium on Modelling of Physiological Flows, Sardinia, Italy, June 02-05, 2010 ; MPF2010 ER - TY - JOUR A1 - Gossmann, Matthias A1 - Thomas, Ulrich A1 - Horváth, András A1 - Dragicevic, Elena A1 - Stoelzle-Feix, Sonja A1 - Jung, Alexander A1 - Raman, Aravind Hariharan A1 - Staat, Manfred A1 - Linder, Peter T1 - A higher-throughput approach to investigate cardiac contractility in vitro under physiological mechanical conditions JF - Journal of Pharmacological and Toxicological Methods Y1 - 2020 U6 - https://doi.org/10.1016/j.vascn.2020.106843 VL - 105 IS - Article 106843 PB - Elsevier CY - New York, NY ER - TY - JOUR A1 - Brockhaus, Moritz K. A1 - Behbahani, Mehdi A1 - Muris, Farina A1 - Jansen, Sebastian V. A1 - Schmitz- Rode, Thomas A1 - Steinseifer, Ulrich A1 - Clauser, Johanna C. T1 - In vitro thrombogenicity testing of pulsatile mechanical circulatory support systems: Design and proof-of-concept JF - Artificial Organs N2 - Thrombogenic complications are a main issue in mechanical circulatory support (MCS). There is no validated in vitro method available to quantitatively assess the thrombogenic performance of pulsatile MCS devices under realistic hemodynamic conditions. The aim of this study is to propose a method to evaluate the thrombogenic potential of new designs without the use of complex in-vivo trials. This study presents a novel in vitro method for reproducible thrombogenicity testing of pulsatile MCS systems using low molecular weight heparinized porcine blood. Blood parameters are continuously measured with full blood thromboelastometry (ROTEM; EXTEM, FIBTEM and a custom-made analysis HEPNATEM). Thrombus formation is optically observed after four hours of testing. The results of three experiments are presented each with two parallel loops. The area of thrombus formation inside the MCS device was reproducible. The implantation of a filter inside the loop catches embolizing thrombi without a measurable increase of platelet activation, allowing conclusions of the place of origin of thrombi inside the device. EXTEM and FIBTEM parameters such as clotting velocity (α) and maximum clot firmness (MCF) show a total decrease by around 6% with a characteristic kink after 180 minutes. HEPNATEM α and MCF rise within the first 180 minutes indicate a continuously increasing activation level of coagulation. After 180 minutes, the consumption of clotting factors prevails, resulting in a decrease of α and MCF. With the designed mock loop and the presented protocol we are able to identify thrombogenic hot spots inside a pulsatile pump and characterize their thrombogenic potential. Y1 - 2021 U6 - https://doi.org/10.1111/aor.14046 SN - 1525-1594 VL - 45 IS - 12 SP - 1513 EP - 1521 PB - Wiley CY - Weinheim ER - TY - JOUR A1 - Knox, Ronald A1 - Bruggemann, Andrea A1 - Gossmann, Matthias A1 - Thomas, Ulrich A1 - Horváth, András A1 - Dragicevic, Elena A1 - Stoelzle-Feix, Sonja A1 - Fertig, Niels A1 - Jung, Alexander A1 - Raman, Aravind Hariharan A1 - Staat, Manfred A1 - Linder, Peter T1 - Combining physiological relevance and throughput for in vitro cardiac contractility measurement JF - Biophysical Journal N2 - Despite increasing acceptance of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in safety pharmacology, controversy remains about the physiological relevance of existing in vitro models for their mechanical testing. We hypothesize that existing signs of immaturity of the cell models result from an improper mechanical environment. We cultured hiPSC-CMs in a 96-well format on hyperelastic silicone membranes imitating their native mechanical environment, resulting in physiological responses to compound stimuli.We validated cell responses on the FLEXcyte 96, with a set of reference compounds covering a broad range of cellular targets, including ion channel modulators, adrenergic receptor modulators and kinase inhibitors. Acute (10 - 30 min) and chronic (up to 7 days) effects were investigated. Furthermore, the measurements were complemented with electromechanical models based on electrophysiological recordings of the used cell types.hiPSC-CMs were cultured on freely-swinging, ultra-thin and hyperelastic silicone membranes. The weight of the cell culture medium deflects the membranes downwards. Rhythmic contraction of the hiPSC-CMs resulted in dynamic deflection changes which were quantified by capacitive distance sensing. The cells were cultured for 7 days prior to compound addition. Acute measurements were conducted 10-30 minutes after compound addition in standard culture medium. For chronic treatment, compound-containing medium was replaced daily for up to 7 days. Electrophysiological properties of the employed cell types were recorded by automated patch-clamp (Patchliner) and the results were integrated into the electromechanical model of the system.Calcium channel agonist S Bay K8644 and beta-adrenergic stimulator isoproterenol induced significant positive inotropic responses without additional external stimulation. Kinase inhibitors displayed cardiotoxic effects on a functional level at low concentrations. The system-integrated analysis detected alterations in beating shape as well as frequency and arrhythmic events and we provide a quantitative measure of these. Y1 - 2020 U6 - https://doi.org/10.1016/j.bpj.2019.11.3104 SN - 0006-3495 N1 - Raman, Arayind Hariharan im Artikel unter dem Namen: Raman, Alexander H. VL - 118 IS - Issue 3, Supplement 1 SP - 570a PB - Elsevier CY - Amsterdam ER - TY - RPRT A1 - Stölzle-Feix, Sonja A1 - Thomas, Ulrich A1 - Engelstädter, Max A1 - Goßmann, Matthias A1 - Linder, Peter A1 - Staat, Manfred A1 - Raman, Aravind Hariharan A1 - Jung, Alexander A1 - Fertig, Niels T1 - Plattformtechnologie für kardiale Sicherheitspharmakologie basierend auf teilsynthetischem Herzmuskelgewebe (FLEXcyte) : gemeinsamer FuE-Abschlussbericht aller Partner des Verbundprojektes : Projektlaufzeit: 01.10.2018 bis 30.09.2020 Y1 - 2021 U6 - https://doi.org/10.2314/KXP:1813208581 N1 - Förderkennzeichen BMBF 02P18K020-021 Verbundnummer 01185221 PB - Nanion Technologies GmbH CY - München ER -